CD46

Across TCGA pan-cancer cohorts, CD46 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD46 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD46 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD46 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where CD46 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.698	1.000	.004	24	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	5	view →
UCEC	OS	Quartile	All	1.000	0.876	.029	4	view →
PDAC	OS	Median	II,III,IV	0.615	0.428	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD46–LUAD (DFS)

Open the LUAD breakdown →